Update on Pediatric Anti-obesity Medications-Current Landscape and Approach to Prescribing.
Curr Obes Rep
; 13(2): 295-312, 2024 Jun.
Article
em En
| MEDLINE
| ID: mdl-38689134
ABSTRACT
PURPOSE OF REVIEW To review the current medical therapies available for treatment of obesity in children and adolescents less than 18 years old in the United States and outline the approach to their use. RECENT FINDINGS:
Obesity is a chronic disease with increasing prevalence in children and adolescents in the United States. Over the past few years, more FDA-approved medical treatments for obesity, such as GLP-1 receptor agonists, have emerged for patients less than 18 years old. Furthermore, there are medications with weight loss effects that can be used off-label for obesity in pediatric patients. However, access to many of these medications is limited due to age restrictions, insurance coverage, and cost. Medical options are improving to provide treatment for obesity in pediatric populations. FDA and off-label medications should be considered when appropriate to treat children and adolescents with obesity. However, further studies are needed to evaluate the efficacy and long-term safety of FDA-approved and off-label medications for obesity treatment in pediatric patients.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Fármacos Antiobesidade
/
Uso Off-Label
/
Obesidade Infantil
Limite:
Adolescent
/
Child
/
Humans
País como assunto:
America do norte
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article